UCL Business, the wholly-owned technology transfer company of UCL, has teamed up with investment group Syncona to create a new biopharmaceutical company called Freeline Therapeutics, which will focus on development and commercialisation of gene therapies for bleeding and other debilitating disorders.
With an investment from Syncona of £25 million in Series A financing and from its base at UCL Royal Free London Hospital, the company will work on gene therapies based on its next-generation adeno-associated virus (AAV) gene therapy platform developed by Amit Nathwani, Professor of Haematology at UCL, the new firm’s chief scientific officer.
AAV is a small virus which infects humans but is not currently known to cause disease, causing a very mild immune response. Properties including its ability to infect both dividing and dormant cells make it an attractive candidate for creating viral vectors for gene therapy.
Freeline’s AAV gene therapy platform builds on the successful haemophilia B Phase I/II trial in which all ten treated haemophilia B patients showed safe, sustained expression of blood clotting Factor IX from a single treatment.
“It is exciting to be building a company on this ground-breaking technology that has the potential to transform the lives of patients with a single administration,” said chairman Chris Hollowood, also a Partner with Syncona LLP.
By Selina McKee
Source: Pharma Times
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
